Abstract
Background: Multi Drug Resistance (MDR) is one of the main hindrances in the successful treatment of cancer by natural agents. Most of the natural anticancer drugs are effluxed by the P-glycoprotein resulting in the failure of cancer chemotherapy. Phenothiazines and related drugs are one of the first drugs investigated for the reversal of MDR. Exhaustive studies have been done to develop potent phenothiazines analogues for MDR reversal activity.
Materials and Methods: Quantitative Structural Activity Relationship (QSAR) and Structural Activity Relationship (SAR) studies of phenothiazines have provided some fruitful results in order to develop potent anti-MDR phenothiazine drugs but no success has been achieved yet. The main mechanism through which phenothiazines act on the Pglycoprotein includes the same binding site of vinblastine drug and it inhibits the efflux of such drugs. To develop a potent anti-MDR agent, it is indispensable to study the mechanism of efflux of anticancer drugs by P-gp, SAR and QSAR studies of phenothiazines as anti-MDR agents and mechanism of phenothiazines as anti-MDR agents simultaneously. Conclusion: This review will discuss the work done on the SAR and QSAR of phenothiazines as anti-MDR agents along with their putative mechanism of action as MDR reversal agents.Keywords: Phenothiazines, p-glycoprotein, MDR, cancer chemotherapy, anti cancer, SAR.
Current Cancer Therapy Reviews
Title:Phenothiazines and Related Drugs as Multi Drug Resistance Reversal Agents in Cancer Chemotherapy Mediated by p-glycoprotein
Volume: 13 Issue: 1
Author(s): Ravinesh Mishra*, Swati Sareen, Bhartendu Sharma, Shubham Goyal, Gurpreet Kaur, Sweta Bhardwaj, Anees A. Siddiqui, Asif Husain, Rajeev K. Singla, Mohd Rashid, Deepak Kumar, Bhawana Sati, Nishtha Shalmali and Rajiv Kumar
Affiliation:
- School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences and Technology, Baddi (Solan), Himachal Pradesh 163205,India
Keywords: Phenothiazines, p-glycoprotein, MDR, cancer chemotherapy, anti cancer, SAR.
Abstract: Background: Multi Drug Resistance (MDR) is one of the main hindrances in the successful treatment of cancer by natural agents. Most of the natural anticancer drugs are effluxed by the P-glycoprotein resulting in the failure of cancer chemotherapy. Phenothiazines and related drugs are one of the first drugs investigated for the reversal of MDR. Exhaustive studies have been done to develop potent phenothiazines analogues for MDR reversal activity.
Materials and Methods: Quantitative Structural Activity Relationship (QSAR) and Structural Activity Relationship (SAR) studies of phenothiazines have provided some fruitful results in order to develop potent anti-MDR phenothiazine drugs but no success has been achieved yet. The main mechanism through which phenothiazines act on the Pglycoprotein includes the same binding site of vinblastine drug and it inhibits the efflux of such drugs. To develop a potent anti-MDR agent, it is indispensable to study the mechanism of efflux of anticancer drugs by P-gp, SAR and QSAR studies of phenothiazines as anti-MDR agents and mechanism of phenothiazines as anti-MDR agents simultaneously. Conclusion: This review will discuss the work done on the SAR and QSAR of phenothiazines as anti-MDR agents along with their putative mechanism of action as MDR reversal agents.Export Options
About this article
Cite this article as:
Mishra Ravinesh *, Sareen Swati , Sharma Bhartendu , Goyal Shubham , Kaur Gurpreet , Bhardwaj Sweta , Siddiqui A. Anees , Husain Asif , Singla K. Rajeev , Rashid Mohd , Kumar Deepak , Sati Bhawana , Shalmali Nishtha and Kumar Rajiv , Phenothiazines and Related Drugs as Multi Drug Resistance Reversal Agents in Cancer Chemotherapy Mediated by p-glycoprotein, Current Cancer Therapy Reviews 2017; 13 (1) . https://dx.doi.org/10.2174/1573394713666170524122904
DOI https://dx.doi.org/10.2174/1573394713666170524122904 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design The Long Term Biological Consequences of Anorexia Nervosa
Current Nutrition & Food Science Stem Cells and Combinatorial Science
Combinatorial Chemistry & High Throughput Screening Tuberculosis, an Old Disease Lacking New Therapeutic Drugs
Current Drug Therapy Leukemia Inhibitory Factor Protects against Degeneration of Cone Photoreceptors Caused by RPE65 Deficiency
Current Medicinal Chemistry Pharmacogenomics of COPD
Current Pharmacogenomics Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Diagnostic Usage of Low Dose CT in Solitary Pulmonary Nodule Follow Up in Daily Practice
Current Medical Imaging Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis
Current Diabetes Reviews Roles of Insulin Resistance, Endothelial Dysfunction and Lifestyle Changes in the Development of Cardiovascular Disease in Diabetic Patients
Current Drug Targets Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Linkage “Body Mass Index-Insomnia Levels-Eating Disorder Flexibility” in Italian Nurses During the Covid-19 Outbreak: A Psychoendocrinological Employment Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Current Pharmaceutical Design MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease
Current Pharmaceutical Design Renal Neoplasia in the Hyperparathyroidism-Jaw Tumor Syndrome
Current Molecular Medicine